The interaction between captopril, an inhibitor of angiotensin converting enzyme and human serum albumin, a principal plasma protein in the liver has been investigated in vitro under a simulated physiological condition by UV-vis spectrophotometry and fluorescence spectrometry. The intrinsic fluorescence intensity of human serum albumin was strongly quenched by captopril. The binding constants and the number of binding sites can be calculated from the data obtained from fluorescence quenching experiments. The negative value of G 0 reveals that the binding process is a spontaneous process. According to the van't Hoff equation, the standard enthalpy change (H 0 ) and standard entropy change (S 0 ) for the reaction were calculated to be 35.98 KJmol -1 and 221.25 Jmol -1 K. It indicated that the hydrophobic interactions play a main role in the binding of captopril to human serum albumin. In addition, the distance between captopril (acceptor) and tryptophan residues of human serum albumin (donor) was estimated to be 1.05 nm according to the Förster's resonance energy transfer theory. The results obtained herein will be of biological significance in pharmacology and clinical medicine.
Introduction
Captopril, as show in Figure 1 , 1-[(2S)-3-mercapto-2-methyl-1-oxopropyl]-L-proline, contains two centers of dissymmetry, one associated with the (S)-proline portion and the other associated with the 3-mercapto-2-methylpropionic acid side chain. As an inhibitor of angiotensin converting enzyme (ACEI) with a short duration of action [1] , it is a drug with a number of cellular actions and clinical applications, and it now extensively used for treatment of chronic heart failure and hypertention [2] for it can catalyze the conversion of angiotensin I to angiotensin II. It has been shown to reduce proteinuria [3] and retard the progression of renal failure in patients with insulin dependent diabetes mellitus and nephropathy, and provides the basis of its use against hypertension. The drug stimulates prostaglandin production and release IL-2 production [4] , and possesses immunosuppressant activity. Besides its vasodilative effects, it possesses inhibiting effects on hypertrophy and remodeling of myocardium without interference with the metabolism of fatty acid, and can improve the patients' quality of life [5, 6] . Some experimental studies have suggested that captopril has antiarrhythmic activity, a reduction of arrhythmias induced by isehemia, reperfusion, or digitalis toxicity [7] . Furthermore, some clinical reports have showed that captopril can decrease the frequency and grade of ventricular ectopy in patients with heart failure or cardiac infarction.
It is well known that protein is an important chemical substance in almost of the life and the main target of all medicines in living beings. Human serum albumin (HSA), the most abundant protein in human plasma, acts as a carrier for transporting many ligands, including fatty acids, amino acids, metal ions, and a variety of pharmaceuticals [8, 9] and disposer of many endogenous and exogenous compounds [10, 15] . It is synthesized in the liver, and exported as a non-glycosylated protein. HSA is a single polypeptide chain of 585 amino acid residues and comprises three structurally homologous domains: I (residues 1-195); II (196-383); and III (384-585). It is folded into three homologous domains each of which contains two subdomains (A and B). HSA has significant physiological function and is one of the model proteins commonly used in methodological research on immunoassay. It can interact with many endogenous and exogenous substances, and it is to bind a wide variety of endogenous and exogenous substances such as, hormones, fatty acids, bilirubin, and foreign molecules such as drugs [16, 17] . It is important to study the interaction of drug with the protein for protein-drug binding plays an important role in pharmacology and pharmacodynamics. The information on the interaction of HSA and drug can help us better understand the absorption and distribution of the drug.
To better understand the pharmacological activities of captopril at molecular level, we characterized the interaction between captopril and HSA by different spectroscopic methods as our previous studies. Efforts were made to investigate the quenching mechanism, binding constants, binding sites, binding mode, and binding distance. Moreover, synchronous fluorescence was employed to probe conformational changes induced by captopril.
Experimental

Apparatus and Reagents
Absorption spectra were recorded on TU1901 UV/Vis Spectrophotometer (PGeneral, Beijing, China). An RF-5301PC fluorescence spectrometer (Jasco, Japan) was applied to record the fluorescence spectra. Deionized water was used for the preparation of some solutions. All chemicals used were of analytical-reagent or higher grade.
General Procedure
All studies were carried out in 10 mL calibrated tubes. In tubes, 1.00 mL known B-R buffer, 1.0 ml of 1.0 × 10 -5 molL -1 HSA solution and a known volume of the standard captopril solution were added. Then the solution was diluted to 10 mL with deionized water and mixed well. After reacted for 20 minutes, the solutions were taken into the optical cell.
The ultraviolet (UV) absorption spectra were measured on a TU1901 UV/Vis Spectrophotometer. The fluorescence spectra of the system were recorded on a FP-6500 fluorescence spectrometer at 300-400 nm. Excitation bandwidth was 3 nm and emission bandwidth was 5 nm, using a 1cm quartz cell. The pH values were measured with a PHS-23 meter.
Results and Discussion
Fluorescence Quenching Spectra and Quenching Mechanism of HSA by Captopril
Any process, which decreases the fluorescence intensity of a sample, is called fluorescence quenching [18] . The basic principles like excited state reactions, molecular rearrangements, energy transfer, ground state complex formation, and collisional quenching involves in molecular interaction, which can result in quenching.
The interaction of captopril with HSA was evaluated by monitoring the intrinsic fluorescence intensity changes of HSA upon addition of captopril. The fluorescence emission spectra of HSA with various amounts of Captopril were recorded on a FP-6500 fluorescence spectrometer at 300 -400 nm following an excitation at 280 nm. Fluorescence quenching spectra of HSA at the presence of various concentrations of captopril are shown in Figure 2 .
As seen in Figure 2 , the addition of captopril led to a concentration-dependent quenching of HSA intrinsic fluorescence intensity along with a slight blue shift of maximum emission wavelength, implying that the binding of captopril to HSA occurs and the microenvironment around the chromophore of HSA is changed upon addition of captopril. With the increasing concentration of captopril, the fluorescence intensity decreased gradually. Such strong quenching clearly indicated the binding of captopril with HSA. Fluorescence quenching could proceed via different mechanisms, usually classified as dynamic quenching and static quenching. Dynamic and static quenching can be distinguished by their different dependence on temperature. Higher temperatures will result in faster diffusion and hence larger amounts of collisional quenching and higher temperatures will typically result in the dissociation of weekly bound complexes and hence smaller amounts of static quenching.
To clarify the fluorescence quenching mechanism induced by HSA, the Stern-Volmer equation Equation (1) was utilized to process the data [19, 20] .
where 0 F and F represent the fluorescence intensities of HSA in the absence and presence of the quencher (captopril).
is the concentration of the quencher, and
is the dynamic quenching constant, which is equal to
K is the bimolecular quenching rate constant and 0  is the average lifetime of the molecule without quencher. In order to confirm the quenching mechanism, the procedure of the fluorescence quenching was first assumed to be dynamic quenching. According to Equation (1), the curve of 0 F F versus was plotted based on the experimental data. The Stern-Volmer curve was linear when the concentration of captopril ranged from 1.25 to 2.75 × 10 −4 molL −1 at 293.15, 300.15 and 310.15 K (see Figure 3) . All the plots show a good linear relationship. As it is known, linear Stern-Volmer plots represent a single quenching mechanism, either static (a formation of a complex be- tween quencher and fluorophore) or dynamic (a collisional process) [21] . In a static quenching process, generally, a linear Stern-Volmer plot indicates either only one drug binding site existing in the proximity of fluorophore or more than one binding site being all equally accessible to quenchers [22, 23] . In a dynamic quenching process, the bimolecular quenching constant K SV is expected to increase with rising temperature because it is closely related to diffusions or diffusion coefficients.
In addition, the Stern-Volmer slope is expected to depend on the concentration of donor (HSA) in a static quenching process, whereas the slope is independent of the concentration of donor in a dynamic process. Linear fittings of the experimental data to Equation (1) afforded K SV and K q listed in Table 1 . Table 1 showed that K SV decreases with increase in temperature. It indicates that the fluorescence quenching of HSA by captopril appears to occur via a dynamic quenching mechanism. K q in Table 1 was calculated by
, and generally the values of 0  for biopolymers were given as 10 Table 1 is of the magnitude of 10 11 L mol
, which is greater than the maximum diffusion collision quenching rate constant (2.0 × 10 10 L mol
) for a variety of quenchers with biopolymer. Therefore, it suggests that the fluorescence quenching process of HSA may be mainly governed by a static quenching mechanism arising from a complex formation rather than a dynamic quenching mechanism [25] . independently bound to a set of equivalent sites on a macromolecule. Thus, the equilibrium between free and bound molecules is given by References [26, 27] . When small molecules were bound independently to a set of equivalent sites on a macromolecule, theequilibrium between free and bound molecules was given by Equation (2) [28] . 
where K b was the binding constant and n was the number of binding sites. For the captopril-HSA system in the lower concentration range, the values for K b and n at different temperatures can be derived from the intercept and slope of Figure 4 based on Equation (2) and presented in Table 2 . Linear regression Equations (4-6) at 290.15, 300.15 and 310.15 K are expressed as follows:
cule and a biomacromolecule include hydrogen bond, van der Waals force, electrostatic and hydrophobic interactions, etc. Because of the -COOH and -SH in the molecular of Captopril, these active groups can interact with the HSA. Thermodynamic parameters for a binding interaction can be used as a major evidence to learn the nature of intermolecular forces. Thus, the temperaturedependent thermodynamic parameters for the captopril-HSA system are used to characterize the intermolecular forces between captopril and HSA. Table 2 shows that there exist a strong interaction between captopril and HSA and a complex formation of captopril with HSA. Furthermore, it can be inferred from the values of n that there is an independent class of binding sites on HSA for captopril. Otherwise, it appears that the binding constants and the number of binding sites increased with increase in temperature [29, 30] . This may be attributed to that the capacity of captopril binding to the fact that HSA is increased with increase in temperature.
Consequently, a free energy change (G 0 ) for a binding interaction at different temperatures can be evaluated:
Mode of Binding from Thermodynamic Parameters
where K is the binding constant and R the gas constant. reveals that the binding process is a spontaneous process. The positive value of S 0 change arises from water molecules arranged more random around HSA and drug, caused by hydrophobic interactions between HSA and drug molecules. Besides, the positive H 0 is considered as another evidence for hydrophobic interactions. Thus, positive values for both H 0 and S 0 indicate hydrophobic interactions playing a major role in captopril binding to HSA [31] .
Conformational Changes Investigated by Synchronous Fluorescence
Synchronous fluorescence is a very useful tool to investigate the microenvironments around the fluorophore functional groups. It is well known that the fluorescence of HSA arises from the tyrosine, tryptophan and phenylalanine residues. The change in HSA conformation upon addition of captopril can be also demonstrated by synchronous fluorescence spectra. As is known, synchronous fluorescence spectra show tyrosine residues of HSA only at the wavelength interval (Δλ) of 15 nm and tryptophan residues of HSA only at Δλ of 60 nm. The effect of captopril on synchronous fluorescence spectra was shown in Figure 5 . The synchronous spectra of captopril-HSA system were scanned at Δλ = 60 nm ( Figure  5(a) ) and Δλ = 15 nm (Figure 5(b) ). The fluorescence of tryptophan ( Figure 5(a) ) was strong, with addition of captopril the fluorescence intensity decreased and no apparent shift occurred in Figure 5 (a). It can be seen the fluorescence spectra of tyrosine ( Figure 5(b) ) was weak and addition of captopril resulted in a decrease in intensity and also no shift of maximum emission wavelength [32] . It indicated that the interaction of captopril with HSA does not significantly affect the conformation of tryptophan and tyrosine residue microregions.
Energy Transform between Captopril and HSA
In order to determine the precise location of captopril in HSA, the efficiency of energy transfer was studied according to the Förster resonance energy transfer theory [33] . The energy transfer was calculated by determination the emission fluorescence of donor and the UV spectra of accepter. The fluorescence quenching of HSA after binding with captopril indicated the transfer of energy between captopril and HSA has occurred. The efficient ligand-protein interaction gives rise to energy, from which the distance between two interacting molecules can be easily evaluated. The efficiency of energy transfer E, is described by the following equation (8) 
where F 0 and F are the fluorescence intensity of donor in the absence and presence of acceptor, respectively, R is the distance between acceptor and donor and R 0 is the critical distance, and the value of R 0 is calculated by following equation:
where K 2 is the spatial orientation factor of the dipole, N is the refractive index of the medium,  is the fluorescence quantum yield of the donor, J is the overlap integral of the fluorescence emission spectrum of the donor and the absorption spectrum of the acceptor. J is given by 
Conclusions
The interaction between captopril and HSA has been investigated by using fluorescence and ultraviolet (UV) absorption spectra in vitro under a simulated physiological condition (pH = 7.24) in this work. The experimental results suggested that the fluorescence of HSA was quenched through static mode, and the pharmaceutical (captopril) can strongly binding to HSA. The synchronous fluorescence spectra showed no significant change in the conformation of HSA upon addition of captopril under experimental conditions; the binding distance R of 1.05 nm between captopril and HSA indicated that the energy transfer from HSA to captopril occurred with high possibility. In addition, the thermodynamic parameter elucidated the binding reaction was mainly driven by hydrophobic interaction.
The determinations performed herein may provide an approach to evaluate the toxic effects of chemicals on target proteins and the molecular mechanism of toxicity. The results obtained herein will be of biological significance in pharmacology and clinical medicine.
Acknowledgements
We thank the National Key Technology R&D Program of China (No.2008BAJ08B13) for financially supporting this work.
References
